Methods of treating or preventing pruritis by blocking natriuretic polypeptide b

Patent metadata

Field	Value
Publication number	US-10583173-B2
Application number	US-201815971671-A
Country	US
Kind code	B2
Filing date	May 4, 2018
Priority date	Dec 5, 2013
Publication date	Mar 10, 2020
Grant date	Mar 10, 2020

Abstract

Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.

First claim

The invention claimed is:

1. A method of treating or reducing pruritis in a mammal in need thereof, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to the mammal in an amount effective to treat or reduce pruritis in the mammal, wherein the Nppb blocking agent is an antibody or antibody fragment that specifically binds to Nppb or natriuretic polypeptide receptor A (Npra).

2. The method of claim 1 , wherein the pruritis is associated with a fungal skin infection.

3. The method of claim 1 , wherein the pruritis is induced by a pruritogen selected from the group consisting of histamine, chloroquine, endothelin (ET-1), 2-methyl serotonin (5HT), SLIGRL-NH2 (PAR2), and compound 48/80 (48/80).

4. The method of claim 1 , wherein the pruritis is associated with renal failure.

5. The method of claim 1 , wherein the pruritis is associated with kidney dialysis.

6. The method of claim 1 , wherein the pruritis is mediated by interleukin (IL)-31.

7. The method of claim 1 , wherein the mammal is a human.

8. The method of claim 1 , wherein the pruritis is associated with a Trichomonas skin infection.

9. The method of claim 1 , wherein the pruritis is associated with eczema.

10. The method of claim 1 , wherein the pruritis is associated with psoriasis.

11. The method of claim 1 , wherein the pruritis is associated with acquired immune deficiency syndrome (AIDS).

12. The method of claim 1 , wherein the pruritis is associated with polycythemia vera.

13. The method of claim 1 , wherein the pruritis is associated with diabetes.

14. The method of claim 1 , wherein the pruritis is associated with hyperthyroidism.

15. The method of claim 1 , wherein the pruritis is associated with liver damage or liver disease.

16. The method of claim 1 , wherein the pruritis is associated with cancer.

17. The method of claim 1 , wherein the pruritis is associated with chemotherapy.

Assignees

• Us Health

Inventors

• Hoon Mark A
• Mishra Santosh K

Classifications

• A01K2217/075

  inducing loss of function, i.e. knock out · CPC title

• C07K16/26

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• C12N15/8509

  for producing genetically modified animals, e.g. transgenic · CPC title

• A61K47/62

  the modifying agent being a protein, peptide or polyamino acid · CPC title

• A01K67/0276

  Knock-out vertebrates · CPC title